Medytox announced on the 11th that its operating profit in the second quarter of this year was 6.3 billion won, a 55.9% decrease compared to the same period last year. During the same period, sales fell 5.2% year-on-year to 61.6 billion won.
However, according to the company, it achieved continuous sales in major businesses such as toxins and fillers, recording over 60 billion won in sales for two consecutive quarters for the first time in its history. In particular, exports of botulinum toxin preparations increased by 17% compared to the previous quarter and by 16% compared to the same period last year.
Medytox plans to increase sales by expanding the number of countries where its botulinum toxin product, 'Newlux,' is registered in the second half of the year. They also expect that the reduction in selling and administrative expenses due to the conclusion of some lawsuits will be reflected in future performance.
A company official said, "We will do our utmost to complete ongoing projects, including the U.S. Food and Drug Administration (FDA) application for the next-generation liquid toxin preparation 'MT10109L,' which is under development for the global market, and the acquisition of approval for the world's first fat-dissolving injection with colic acid component 'MT921.'"